“AZ 960”的搜索结果

29 个项目

每页

设置升序顺序
  1. AZD1480

    Catalog No. A10110
    Quick View
    JAK 抑制剂
    AZD1480是一种新型有效的小型JAK2抑制剂,IC50为0.26 nM。 了解更多
  2. AZD8931 (Sapitinib)

    Catalog No. A10116
    Quick View
    pan-EGFR/pan-erbB 抑制剂
    AZD8931 (Sapitinib)是ErbB1,ErbB2和ErbB3受体信号传导的等效抑制剂。 了解更多
  3. AZD1208

    Catalog No. A13203
    Quick View
    pan-Pim kinase 抑制剂
    AZD1208是PIM激酶的小分子抑制剂,具有潜在的抗肿瘤活性。 了解更多
  4. AZD-9291 (Osimertinib)

    Catalog No. A13681
    Quick View
    EGFR 抑制剂
    AZD-9291 (Osimertinib)是第三代EGFR抑制剂,在临床前研究中显示出希望,并为已对现有EGFR抑制剂产生耐药性的晚期肺癌患者提供了希望。 了解更多
  5. SD 1008

    Catalog No. A15364
    Quick View
    JAK2/STAT3 抑制剂
    SD 1008是JAK2/STAT3信号通路抑制剂,可额外抑制Src。注意到SD 1008可诱导表达组成性活性酪氨酸磷酸化STAT3的细胞系凋亡。 了解更多
  6. AZ5104

    Catalog No. A15516
    Quick View
    EGFR 抑制剂
    AZD-9291的去甲基代谢产物AZ5104是一种有效的EGFR抑制剂,对于EGFR(L858R/T790M),EGFR(L858R),EGFR(L861Q)和EGFR,IC50 <1 nM,6 nM,1 nM和25 nM EGFR(野生型)。 了解更多
  7. AZD3759

    Catalog No. A15551
    Quick View
    EGFR 抑制剂
    AZD3759是表皮生长因子受体(EGFR)的口服抑制剂。它结合并抑制EGFR以及某些突变形式的EGFR的活性。 了解更多
  8. EGF816 (Nazartinib)

    Catalog No. A14416
    Quick View
    EGFR T790M 抑制剂
    EGF816 (Nazartinib)是新型的突变选择性EGFR共价抑制剂。克服了NSCLC中T790M介导的耐药性。 了解更多
  9. Nifuroxazide

    Catalog No. A16220
    Quick View
    STAT 抑制剂
    Nifuroxazide是STAT激活和信号传导活性的抑制剂,是一种口服硝基呋喃抗生素,用于治疗人类和非人类的结肠炎和腹泻。 了解更多
  10. Lazertinib (YH25448,GNS-1480)

    Catalog No. A16827
    Quick View
    EGFR 抑制剂
    Lazertinib (YH25448,GNS-1480)是一种有效的,高度突变选择性和不可逆的EGFR-TKI,对于Del19/T790M,L858R/T790M,Del19,Del19,IC50值分别为1.7 nM,2 nM,5 nM,20.6 nM和76 nM。L85R和野生型EGFR分别显示出更高的IC50值,即抗药性ErbB2和ErbB4。 了解更多
  11. AZD1208 HCl

    Catalog No. A16927
    Quick View
    PIM kinases 抑制剂
    AZD1208 HCl是一种新型的,口服可生物利用的高选择性PIM激酶抑制剂。 了解更多
  12. WHI-P258

    Catalog No. A18317
    Quick View
    JAK3 抑制剂
    WHI-P258 is a quinazoline compound that modeling studies suggested would bind to the active site of JAK3 with an estimated Ki value of 72 uM. 了解更多
  13. Tyk2-IN-8

    Catalog No. A19052
    Quick View
    TYK2 抑制剂
    Tyk2-IN-8 (compound 10) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain with an IC50 of 17 nM, used in the treatment of psoriasis. 了解更多
  14. JAK1-IN-7

    Catalog No. A19029
    Quick View
    JAK1 抑制剂
    JAK1-IN-7 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect. 了解更多
  15. JAK3 covalent inhibitor-1

    Catalog No. A18926
    Quick View
    JAK3 covalent 抑制剂
    JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. 了解更多
  16. JAK1-IN-4

    Catalog No. A18821
    Quick View
    JAK1 抑制剂
    JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM). 了解更多
  17. Mutated EGFR-IN-2

    Catalog No. A18565
    Quick View
    EGFR 抑制剂
    Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=??1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. 了解更多
  18. Epertinib

    Catalog No. A13777
    Quick View
    EGFR/HER2/HER4 inhibitor
    Epertinib is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib shows potent antitumor activity. 了解更多
  19. EGFR-IN-2

    Catalog No. A12628
    Quick View
    EGFR inhibitor
    EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. 了解更多
  20. CHMFL-EGFR-202

    Catalog No. A12524
    Quick View
    EGFR inhibitor
    CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. 了解更多
  21. JAK2-IN-4

    Catalog No. A12182
    Quick View
    JAK2/JAK3 inhibitor
    JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively. 了解更多
  22. JAK-IN-1

    Catalog No. A21237
    Quick View
    JAK1/2/3 inhibitor
    JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. 了解更多
  23. Tyk2-IN-7

    Catalog No. A21491
    Quick View
    TYK2 JH2 inhibitor
    Tyk2-IN-7 (Compound 48) is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. 了解更多
  24. Momelotinib Mesylate

    Catalog No. A21658
    Quick View
    JAK1/JAK2 inhibitor
    Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. 了解更多
  25. Nazartinib mesylate

    Catalog No. A21741
    Quick View
    covalent mutant-selective EGFR inhibitor
    Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. 了解更多
  26. Nazartinib S-enantiomer

    Catalog No. A21747
    Quick View
    EGFR inhibitor
    Nazartinib S-enantiomer (EGF816 S-enantiomer) is the less active S-enantiomer of Nazartinib. Nazartinib (EGF816) is an EGFR inhibitor. 了解更多
  27. BMS-066

    Catalog No. A21972
    Quick View
    IKKβ/Tyk2 pseudokinase inhibitor
    BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively. 了解更多
  28. Tyk2-IN-3

    Catalog No. A21982
    Quick View
    Tyk2 pseudokinase inhibitor
    Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM. 了解更多
  29. AZ-960

    Catalog No. A10104
    Quick View
    JAK2抑制剂
    AZ-960是一种有效的,选择性的和ATP竞争性的JAK2抑制剂,在体外抑制JAK2激酶的Ki为0.45 nM,并诱导成年T细胞白血病(ATL)细胞的生长停滞和凋亡 了解更多

29 个项目

每页

设置升序顺序
Rewards